Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Change in Receivables: 2011-2024

Historic Change in Receivables for Mimedx Group (MDXG) over the last 13 years, with Dec 2024 value amounting to $2.6 million.

  • Mimedx Group's Change in Receivables rose 1055.72% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.8 million, marking a year-over-year increase of 372.35%. This contributed to the annual value of $2.6 million for FY2024, which is 79.15% down from last year.
  • According to the latest figures from FY2024, Mimedx Group's Change in Receivables is $2.6 million, which was down 79.15% from $12.2 million recorded in FY2023.
  • Over the past 5 years, Mimedx Group's Change in Receivables peaked at $12.2 million during FY2023, and registered a low of $2.6 million during FY2024.
  • Its 3-year average for Change in Receivables is $6.9 million, with a median of $5.9 million in 2022.
  • As far as peak fluctuations go, Mimedx Group's Change in Receivables spiked by 243.02% in 2021, and later plummeted by 79.15% in 2024.
  • Over the past 5 years, Mimedx Group's Change in Receivables (Yearly) stood at $3.1 million in 2020, then skyrocketed by 243.02% to $10.6 million in 2021, then plummeted by 44.10% to $5.9 million in 2022, then soared by 106.11% to $12.2 million in 2023, then plummeted by 79.15% to $2.6 million in 2024.